Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims To investigate whether the satiety‐inducing agent sibutramine affected body weight and associated anthropometry in overweight and obese (body mass index (BMI) > 27) Type 2 diabetic patients on sulphonylurea therapy. Methods A randomized, placebo‐controlled trial was undertaken in 134 patients with stable metabolic control on chronic sulphonylurea therapy. Patients were placed on moderate caloric restriction and received treatment with either sibutramine (15 mg/day) or placebo for 6 months. Results Fifty‐three of 69 sibutramine‐treated and 57/65 placebo‐treated patients completed the study. Both groups showed progressive weight loss. At the end of the trial weight loss was two times greater in the sibutramine group (mean ± sem; −4.5 ± 0.5 kg) than placebo (−1.7 ± 0.5 kg, P < 0.001 vs. sibutramine). There was a trend for more patients to lose > 5% of initial body weight in the sibutramine group than placebo. BMI (P < 0.001) and waist circumference (P < 0.001) were also decreased to a greater extent by sibutramine. Mean reductions in HbA 1c were commensurate with weight loss in both the sibutramine and placebo (−0.78 ± 0.17% and −0.73 ± 0.23%; P = 0.84). Sibutramine was well tolerated with only two patients withdrawn due to potentially drug‐related serious adverse events (palpitations). Conclusions Sibutramine, in conjunction with moderate caloric restriction, enhances weight loss and reduces waist circumference in overweight and obese Type 2 diabetic patients receiving sulphonylurea therapy. This is associated with additional improvements in glycaemic control in a limited number of patients losing ≥ 10% of their baseline body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Suggestion for Using Powerful and Informative Tests of Normality
D'agostino, R. B., Belanger, A., & D'agostino, R. B. (1990) · The American Statistician · doi:10.2307/2684359 · Cited by 1,809
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Cited by
Effect of thiazolidinediones on body weight in patients with diabetes mellitus
Fonseca, V. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.005 · Cited by 283
The Efficacy and Safety of Sibutramine for Weight Loss: A Systematic Review
Arterburn, D. E., Crane, P. K., & Veenstra, D. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.994 · Cited by 254
Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12971 · Cited by 162
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes
Redmon, J. B., Reck, K. P., Raatz, S. K., Swanson, J. E., Kwong, C. A., Ji, H., Thomas, W., & Bantle, J. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1311 · Cited by 66
Metadata
- Authors
- Serrano‐Rios, M., Melchionda, N., & Moreno‐Carretero, E.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 19
- Issue
- 2
- Pages
- 119-124
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1749417091
- Cited by
- 69
- References
- 5
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.